Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 23,669 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 23,669 shares of the company's stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $36.13, for a total value of $855,160.97. Following the transaction, the chief executive officer directly owned 514,982 shares of the company's stock, valued at approximately $18,606,299.66. The trade was a 4.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ying Du also recently made the following trade(s):

• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total transaction of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The shares were sold at an average price of $28.09, for a total transaction of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The shares were sold at an average price of $33.11, for a total value of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The stock was sold at an average price of $35.89, for a total value of $208,449.12.

Zai Lab Trading Up 0.7%

Zai Lab stock traded up $0.23 during midday trading on Monday, hitting $34.97. 847,285 shares of the stock were exchanged, compared to its average volume of 909,132. The stock's 50-day simple moving average is $33.57 and its 200 day simple moving average is $31.19. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $16.01 and a fifty-two week high of $44.34. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of -14.04 and a beta of 0.96.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.05. The firm had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. Equities analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Zai Lab

Large investors have recently modified their holdings of the business. FMR LLC increased its position in shares of Zai Lab by 749.1% during the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock worth $143,403,000 after purchasing an additional 4,830,646 shares during the last quarter. Principal Financial Group Inc. lifted its position in Zai Lab by 63.6% in the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after buying an additional 1,121,856 shares during the last quarter. RTW Investments LP purchased a new position in Zai Lab during the fourth quarter worth about $65,714,000. Price T Rowe Associates Inc. MD increased its position in shares of Zai Lab by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock valued at $61,653,000 after acquiring an additional 548,378 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after acquiring an additional 2,127,598 shares during the period. Institutional investors and hedge funds own 41.65% of the company's stock.

Analysts Set New Price Targets

ZLAB has been the topic of several recent research reports. Wall Street Zen cut shares of Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday. Leerink Partners boosted their price target on shares of Zai Lab from $73.00 to $75.00 and gave the stock an "outperform" rating in a research report on Monday. Scotiabank initiated coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective for the company. Bank of America reiterated a "neutral" rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $54.28.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.